Medical oncology is an essential component of BID–Needham's comprehensive approach to treating and managing women with gynecologic cancer. BID–Needham's medical gynecologic oncologists are fellowship trained clinicians and accomplished clinical investigators. They are members of the Dana Farber/Harvard Cancer Center and play a critical role in developing novel therapeutics involving chemotherapy and biologic agents for gynecologic malignancies. Our physicians offer patients state of the art clinical trials that include the use of antiangiogenesis agents, novel drugs for recurrent disease, and innovative maintenance chemotherapy approaches. They were the first to pioneer the use of gene expression profiling (genomics) as a prognostic tool in ovarian cancer and are now extending these observations to predict the likelihood that individual patients will respond to chemotherapy.